Mode
Text Size
Log in / Sign up
N/A N=142 Randomized Single-blind Other

Articulating Enseal Versus Ligasure Energy Devices

Task Performance

Enrolled (actual)
142
Serious AEs
2.1%
Results posted
Jan 2018
Primary outcome: Primary: Raw Task Load Index (TLX) Score Assigned by Surgeons — 51.7; 32.5 units on a scale — p=0.0001

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
articulating Enseal (Device); Ligasure device (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
Female
Sponsor
University of Louisville
Primary completion
Apr 2016

Outcome Measures

OutcomeResultp-value
PRIMARY
Raw Task Load Index (TLX) Score Assigned by Surgeons
51.7; 32.5 0.0001 sig
SECONDARY
Intra- and Post-operative Complications
1; 2 1.00
SECONDARY
Estimated Blood Loss
100; 100 0.582
SECONDARY
Need for Second Energy Device Intra-operatively
10; 0 0.0031 sig
SECONDARY
Time From Port Placement to Bilateral Uterine Artery Ligation and Hemostatsis.
35; 30 0.0281 sig
SECONDARY
Time Required to Complete Procedure
97; 85 .0821

Summary

This is an exploratory study to assess the ability of the raw-TLX (raw Task Load Index) ergonomic assessment tool to detect differences in surgeon workload when using commercially available advanced bipolar devices. It is anticipated that the raw-TLX version of the validated NASA-TLX ergonomic assessment tool will detect less surgeon effort required in the procedure when articulating ENSEAL is utilized. The Articulating ENSEAL device may also positively impact other variables such as blood loss, operative time and cost.

Eligibility Criteria

Inclusion Criteria

  • Age 18 or older
  • Able and willing to provide informed consent
  • Undergoing total laparoscopic hysterectomy

Exclusion Criteria

  • Under 18 years of age
  • Severe endometriosis or adhesions requiring >15min of adhesiolysis prior to beginning hysterectomy
  • Unsafe to use energy device due to decreased visualization or any other reason deemed to be unsafe by the surgeon intra-operative decision to convert to laparotomy prior to use of energy device
  • Current diagnosis of uterine, tubal ovarian or cervical malignancy.
  • Patients who cannot read/understand English.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02163538). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search